reason report
present ad data affirm continu long-term
bottom line follow top-line posit data topic jakafi
ruxolitinib cream atop dermat ad
trial see takeaway
mp present detail data late-break session
overal detail data consist top-line data show
significantli patient treat topic jakafi
twice daili bid achiev iga-t primari endpoint
itch nr secondari endpoint versu vehicl control
studi detail data also show
well-toler safeti profil topic jakafi cream addit
compani re-affirm key mileston busi continu
pandem believ boost share today line
gener market howev level believ
dermatolog franchis opportun fulli reflect share key
debat commerci opportun topic ruxolitinib cream
area brand cream commerci disappoint
date see commerci debat resolv late
key lever like abil compani
captur sever patient without data patient
use combin system agent backbon
therapi believ investor may look cash-flow positive/
neutral biotech compani macro condit improv think
share less impact see littl upsid
level drive invest thesi maintain mp
detail data show consist efficaci topic jakafi
detail present
studi achiev primari endpoint proport patient
ts consist prior top-line data releas trial
patient treat bid patient treat
bid vs vehicl control achiev iga-t
week also patient bid cohort
patient vs vehicl control achiev
eczema area sever index score improv baselin
patient treat bid patient treat
bid vs vehicl control achiev iga-t also
patient bid patient bid vs
control achiev score improv baselin
detail data also show significantli patient treat
topic jakafi cream demonstr clinic
meaning itch reduct defin improv itch nr
numer rate score vs vehicl week overal detail
data favor consist prior phase data
net debt total capit
price-to-earnings lt ep growth
net debt total capit calcul use bv
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep
pleas refer page import disclosur price chart analyst certif
topic jakafi cream appear well toler on-going
long-term safeti evalu remain key studi
treatment overal treatment-emerg advers event teae
compar among bid bid vehicl control
respect true-
respect studi rate seriou
advers event also compar bid bid
vehicl control respect
respect seriou teae
relat topic jakafi treatment treatment-rel advers event
trae mild moder sever common trae
applic site burn applic site pruritu pruritu
teae suggest relationship system exposur overal
safeti profil topic jakafi appear well toler long-term
safeti evalu extens treatment current underway
remain key support topic jakafi cream approv
commerci opportun debat data
favor mild moder ad patient key debat remain
whether compani turn dermatolog franchis multi-
blockbust opportun topic agent fail key
lever view abil compani success
captur sever patient like compliant
intervent model peak estim ad alreadi
reflect penetr sever ad patient repres
assess opportun howev note
compani data set efficaci safeti
like top system drug view remain
seen whether anecdot experi drive usag
sever patient overal safeti drug qualiti label
black box black box may import factor
regulatori submiss topic jakafi remain track
key mileston also track new drug applic
nda topic jakafi cream remain track submit
pend long-term safeti data
extens studi suggest launch late given time
nda submiss anticip approv updat
confer call includ impact commerci execut
suppli chain well limit impact key mileston
includ regulatori action pemigatinib tafasitamab
rate corp share market perform commerci stage
biotechnolog compani develop drug modul pathway involv cell signal
oncolog autoimmun disord compani solid backbon revenu lead
asset jakafi oral inhibitor jak pathway estim worth per share
howev see compani execut goal diversifi revenu see stock
fulli valu favor upcom catalyst potenti competit fedratinib gener
eros anticip promis asset pipelin think
opportun alreadi larg reflect share howev share could repres
good invest investor longer term horizon beyond one year valuat
will invest mid-cap biotechnolog compani solid financi fundament
use risk-adjust sum-of-the-part methodolog valu examin clinic
regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate
cash flow gener asset determin total net present valu
risk-adjust asset total npv reflect remain clinic regulatori risk
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current value/sharejakafi polycythemia eu us ra eu ra ad indic inhibit fgfr fl mcl cmet ww jak atop jak us r/r regulatori eu r/r oncolog pipelinei ii asset share count total risk-adjust equiti valu risk residu non-deplet profitabilityincyt corpor mf/pvolumianticlusigjak jaktafasitamab dlbclearli oncolog pipelin te corpor
commerci risk competit compani develop treatment myelofibrosi
polycythemia vera therapeut area compet repres risk
clinic risk clinic trial failur incyt compound develop includ itacitinib
pemigatinib ruxolitinib compani earli stage pipelin repres risk
current valuat
regulatori risk even posit clinic data regulatori approv need market
prescript drug develop market regul may declin approv applic
incyt development-stag compound repres risk current valuat
companyprogram/drugtherapeut areaeventtimingev typetri phaseincytepemigatinibcholangiocarcinomapotenti us approv cholangiocarcinoma may tafasitamabdiffus larg cell lymphoma submiss tafasitamab r/r dlbcl combin data inhibitor trial dataphiincytejakafimyelofibrosisproof-of-concept combin data pim inhibitor jakafi trial dataphiincyt tafasitamabdiffus larg cell lymphoma potenti us approv r/r dlbcl august dermatitispotenti nda submiss topic non-smal cell lung cancerpotenti fda approv met-mut vs host diseasedata phiii trial steroid refractori chronic trial dataphiiiincyteparsaclisibfollicular lymphomapotenti data phii r/r trial dataphiiincyteparsaclisibmargin zone lymphomapotenti data phii r/r trial dataphiiincyteparsaclisibmantl cell lymphomapotenti data phii r/r trial datapiiincytepemigatinibbladd cancerdata phii trial pemigatinib metastat bladder cancer trial cancerdata phii trial r/r anal trial dataphiiincytejakafiatop dermatitispotenti us fda approv topic vs host diseasedata trial chronic trial dataphiiiincyt catalyst corpor
 mn except ep
product revenu
chang fair valu acquisition-rel conting consider
earn tax ebt
balanc sheet mn
compani report svb leerink estim
